NASDAQ:TGTX TG Therapeutics Q3 2026 Earnings Date & Estimates $60.75 +0.80 (+1.33%) Closing price 11/3/2026 04:00 PM EasternExtended Trading$61.55 +0.80 (+1.32%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. TG Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from TG Therapeutics in Q3 2026TG Therapeutics is expected to post earnings of $0.3668 per share on revenue of $245.47 million. In the same quarter a year earlier TG Therapeutics reported $2.43 per share. TG Therapeutics last reported on August 3, 2026, posting $0.05 per share and missing the $0.3057 consensus estimate. TG Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.3668Expected Revenue$245.47 millionPrior-Year EPS$2.43Expected EPS Growth-84.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.05 (Missed by -$0.2557)Last Quarter Revenue$240.34 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report TG Therapeutics Q3 2026 Earnings FAQ When does TG Therapeutics report Q3 2026 earnings? TG Therapeutics (NASDAQ:TGTX) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is TG Therapeutics' Q3 2026 earnings call? TG Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for TG Therapeutics? Analysts expect TG Therapeutics to post earnings of $0.3668 per share for Q3 2026. How much revenue is TG Therapeutics expected to report? The consensus revenue estimate for TG Therapeutics is $245.47 million for Q3 2026. TG Therapeutics Earnings HeadlinesTG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business UpdateNovember 2 at 8:00 AM | businesswire.comTGTX stock hits fresh 52-week high ahead of earnings amid buyout buzzOctober 30, 2026 | msn.comFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks. | Weiss Ratings (Ad)TG Therapeutics (TGTX) Stock May Be Underpriced Relative To EarningsOctober 28, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and TG Therapeutics (TGTX)October 27, 2026 | theglobeandmail.comWhy TG Therapeutics (TGTX) Shares Climbed After Its Latest UpdateOctober 27, 2026 | finance.yahoo.comSee More TG Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TG Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TG Therapeutics and other key companies, straight to your email. Email Address About TG TherapeuticsTG Therapeutics (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system. TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults. BRIUMVI is administered by intravenous infusion and is designed to reduce the number of B cells involved in the disease process. The company previously developed UKONIQ (umbralisib), a treatment for certain types of lymphoma, but voluntarily withdrew the product from the U.S. market in 2022 following discussions with the U.S. Food and Drug Administration concerning safety findings. TG Therapeutics continues to focus on BRIUMVI and its broader pipeline of investigational therapies for immune-mediated and hematologic diseases. Michael S. Weiss serves as the company’s chief executive officer and executive chairman.View TG Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestApple's Earnings Beat Comes With a Catch for Investors Heading Into the HolidaysRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)Devon Energy (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
